Tumor heterogeneity has been suggested as an explanation for the development of resistance to anti-HER2 therapies in breast carcinoma patients and might be the cause of a so-called mixed response to HER2-targeted therapy (34). This evidence concerns the gene ERBB2 and breast carcinoma.